Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Neurology Clinical Trials Market Overview
3.1 Global Neurology Clinical Trials Market Historical Value (2019-2025)
3.2 Global Neurology Clinical Trials Market Forecast Value (2026-2035)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Neurology Clinical Trials Market Landscape*
5.1 Global Neurology Clinical Trials Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Neurology Clinical Trials Market: Product Landscape
5.2.1 Analysis by Type
5.2.2 Analysis by Indication
5.2.3 Analysis by Study Design
6 Global Neurology Clinical Trials Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Neurology Clinical Trials Market Segmentation (2019-2035)
7.1 Global Neurology Clinical Trials Market (2019-2035) by Type
7.1.1 Market Overview
7.1.2 Phase I
7.1.3 Phase II
7.1.4 Phase III
7.1.5 Phase IV
7.2 Global Neurology Clinical Trials Market (2019-2035) by Indication
7.2.1 Market Overview
7.2.2 Epilepsy
7.2.3 Stroke
7.2.4 Alzheimer's Disease (AD)
7.2.5 Parkinson's Disease (PD)
7.2.6 Traumatic Brain Injury (TBI)
7.2.7 Amyotrophic Lateral Sclerosis (ALS)
7.2.8 Others
7.3 Global Neurology Clinical Trials Market (2019-2035) by Study Design
7.3.1 Market Overview
7.3.2 Interventional
7.3.3 Observational
7.3.4 Expanded Access
7.4 Global Neurology Clinical Trials Market (2019-2035) by Region
7.4.1 Market Overview
7.4.2 North America
7.4.3 Europe
7.4.4 Asia Pacific
7.4.5 Latin America
7.4.6 Middle East and Africa
8 North America Neurology Clinical Trials Market (2019-2035)
8.1 North America Neurology Clinical Trials Market (2019-2035) by Type
8.1.1 Market Overview
8.1.2 Phase I
8.1.3 Phase II
8.1.4 Phase III
8.1.5 Phase IV
8.2 North America Neurology Clinical Trials Market (2019-2035) by Indication
8.2.1 Market Overview
8.2.2 Epilepsy
8.2.3 Stroke
8.2.4 Alzheimer's Disease (AD)
8.2.5 Parkinson's Disease (PD)
8.2.6 Traumatic Brain Injury (TBI)
8.2.7 Amyotrophic Lateral Sclerosis (ALS)
8.2.8 Others
8.3 North America Neurology Clinical Trials Market (2019-2035) by Study Design
8.3.1 Market Overview
8.3.2 Interventional
8.3.3 Observational
8.3.4 Expanded Access
8.4 North America Neurology Clinical Trials Market (2019-2035) by Country
8.4.1 United States of America
8.4.1.1 United States of America Neurology Clinical Trials Market (2019-2035) by Type
8.4.2 Canada
8.4.2.1 Canada Neurology Clinical Trials Market (2019-2035) by Type
9 Europe Neurology Clinical Trials Market (2019-2035)
9.1 Europe Neurology Clinical Trials Market (2019-2035) by Type
9.1.1 Market Overview
9.1.2 Phase I
9.1.3 Phase II
9.1.4 Phase III
9.1.5 Phase IV
9.2 Europe Neurology Clinical Trials Market (2019-2035) by Indication
9.2.1 Market Overview
9.2.2 Epilepsy
9.2.3 Stroke
9.2.4 Alzheimer's Disease (AD)
9.2.5 Parkinson's Disease (PD)
9.2.6 Traumatic Brain Injury (TBI)
9.2.7 Amyotrophic Lateral Sclerosis (ALS)
9.2.8 Others
9.3 Europe Neurology Clinical Trials Market (2019-2035) by Study Design
9.3.1 Market Overview
9.3.2 Interventional
9.3.3 Observational
9.3.4 Expanded Access
9.4 Europe Neurology Clinical Trials Market (2019-2035) by Country
9.4.1 United Kingdom
9.4.1.1 United Kingdom Neurology Clinical Trials Market (2019-2035) by Type
9.4.2 Germany
9.4.2.1 Germany Neurology Clinical Trials Market (2019-2035) by Type
9.4.3 France
9.4.3.1 France Neurology Clinical Trials Market (2019-2035) by Type
9.4.4 Italy
9.4.4.1 Italy Neurology Clinical Trials Market (2019-2035) by Type
9.4.5 Others
10 Asia Pacific Neurology Clinical Trials Market (2019-2035)
10.1 Asia Pacific Neurology Clinical Trials Market (2019-2035) by Type
10.1.1 Market Overview
10.1.2 Phase I
10.1.3 Phase II
10.1.4 Phase III
10.1.5 Phase IV
10.2 Asia Pacific Neurology Clinical Trials Market (2019-2035) by Indication
10.2.1 Market Overview
10.2.2 Epilepsy
10.2.3 Stroke
10.2.4 Alzheimer's Disease (AD)
10.2.5 Parkinson's Disease (PD)
10.2.6 Traumatic Brain Injury (TBI)
10.2.7 Amyotrophic Lateral Sclerosis (ALS)
10.2.8 Others
10.3 Asia Pacific Neurology Clinical Trials Market (2019-2035) by Study Design
10.3.1 Market Overview
10.3.2 Interventional
10.3.3 Observational
10.3.4 Expanded Access
10.4 Asia Pacific Neurology Clinical Trials Market (2019-2035) by Country
10.4.1 China
10.4.1.1 China Neurology Clinical Trials Market (2019-2035) by Type
10.4.2 Japan
10.4.2.1 Japan Neurology Clinical Trials Market (2019-2035) by Type
10.4.3 India
10.4.3.1 India Neurology Clinical Trials Market (2019-2035) by Type
10.4.4 ASEAN
10.4.4.1 ASEAN Neurology Clinical Trials Market (2019-2035) by Type
10.4.5 Australia
10.4.5.1 Australia Neurology Clinical Trials Market (2019-2035) by Type
10.4.6 Others
11 Latin America Neurology Clinical Trials Market (2019-2035)
11.1 Latin America Neurology Clinical Trials Market (2019-2035) by Type
11.1.1 Market Overview
11.1.2 Phase I
11.1.3 Phase II
11.1.4 Phase III
11.1.5 Phase IV
11.2 Latin America Neurology Clinical Trials Market (2019-2035) by Indication
11.2.1 Market Overview
11.2.2 Epilepsy
11.2.3 Stroke
11.2.4 Alzheimer's Disease (AD)
11.2.5 Parkinson's Disease (PD)
11.2.6 Traumatic Brain Injury (TBI)
11.2.7 Amyotrophic Lateral Sclerosis (ALS)
11.2.8 Others
11.3 Latin America Neurology Clinical Trials Market (2019-2035) by Study Design
11.3.1 Market Overview
11.3.2 Interventional
11.3.3 Observational
11.3.4 Expanded Access
11.4 Latin America Neurology Clinical Trials Market (2019-2035) by Country
11.4.1 Brazil
11.4.1.1 Brazil Neurology Clinical Trials Market (2019-2035) by Type
11.4.2 Argentina
11.4.2.1 Argentina Neurology Clinical Trials Market (2019-2035) by Type
11.4.3 Mexico
11.4.3.1 Mexico Neurology Clinical Trials Market (2019-2035) by Type
11.4.4 Others
12 Middle East and Africa Neurology Clinical Trials Market (2019-2035)
12.1 Middle East and Africa Neurology Clinical Trials Market (2019-2035) by Type
12.1.1 Market Overview
12.1.2 Phase I
12.1.3 Phase II
12.1.4 Phase III
12.1.5 Phase IV
12.2 Middle East and Africa Neurology Clinical Trials Market (2019-2035) by Indication
12.2.1 Market Overview
12.2.2 Epilepsy
12.2.3 Stroke
12.2.4 Alzheimer's Disease (AD)
12.2.5 Parkinson's Disease (PD)
12.2.6 Traumatic Brain Injury (TBI)
12.2.7 Amyotrophic Lateral Sclerosis (ALS)
12.2.8 Others
12.3 Middle East and Africa Neurology Clinical Trials Market (2019-2035) by Study Design
12.3.1 Market Overview
12.3.2 Interventional
12.3.3 Observational
12.3.4 Expanded Access
12.4 Middle East and Africa Neurology Clinical Trials Market (2019-2035) by Country
12.4.1 Saudi Arabia
12.4.1.1 Saudi Arabia Neurology Clinical Trials Market (2019-2035) by Type
12.4.2 United Arab Emirates
12.4.2.1 United Arab Emirates Neurology Clinical Trials Market (2019-2035) by Type
12.4.3 Nigeria
12.4.3.1 Nigeria Neurology Clinical Trials Market (2019-2035) by Type
12.4.4 South Africa
12.4.4.1 South Africa Neurology Clinical Trials Market (2019-2035) by Type
12.4.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Strategic Initiatives
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Initiatives
16.3 Analysis by Joint Ventures
16.4 Analysis by Leading Players
16.5 Analysis by Geography
17 Supplier Landscape
17.1 Market Share Analysis, By Region (For Top 5 Companies)
17.1.1 Market Share Analysis: Global
17.1.2 Market Share Analysis: North America
17.1.3 Market Share Analysis: Europe
17.1.4 Market Share Analysis: Asia Pacific
17.1.5 Market Share Analysis: Others
17.2 Supernus Pharmaceuticals, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Company News and Development
17.2.5 Certifications
17.3 AstraZeneca plc
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Company News and Development
17.3.5 Certifications
17.4 Aurobindo Pharma
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Company News and Development
17.4.5 Certifications
17.5 Eisai Co., Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Company News and Development
17.5.5 Certifications
17.6 Eli Lilly and Company
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Company News and Development
17.6.5 Certifications
17.7 Aurora Health Care
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Company News and Development
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Company News and Development
17.8.5 Certifications
17.9 Zydus Group
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Company News and Development
17.9.5 Certifications
17.10 Athira Pharma, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Company News and Development
17.10.5 Certifications
17.11 Annovis Bio
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Company News and Development
17.11.5 Certifications
18 Global Neurology Clinical Trials Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total branded market. The Informes de Expertos (IDE) team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.